IFP Advisors Inc boosted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 7.1% during the second quarter, Holdings Channel reports. The fund owned 6,736 shares of the medical research company’s stock after buying an additional 447 shares during the period. IFP Advisors Inc’s holdings in Edwards Lifesciences Corporation were worth $796,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of EW. Quadrant Capital Group LLC boosted its stake in Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock worth $109,000 after buying an additional 41 shares in the last quarter. YorkBridge Wealth Partners LLC bought a new stake in Edwards Lifesciences Corporation during the first quarter worth approximately $110,000. NEXT Financial Group Inc boosted its stake in Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock worth $115,000 after buying an additional 500 shares in the last quarter. Cornerstone Advisors Inc. boosted its stake in Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after buying an additional 219 shares in the last quarter. Finally, Alexandria Capital LLC boosted its stake in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares in the last quarter. 84.15% of the stock is currently owned by institutional investors.

Edwards Lifesciences Corporation (NYSE EW) opened at 114.13 on Friday. The firm has a 50-day moving average price of $117.06 and a 200-day moving average price of $105.21. The company has a market cap of $24.10 billion, a P/E ratio of 34.62 and a beta of 0.63. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.20. The business had revenue of $842 million for the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.76 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “IFP Advisors Inc Purchases 447 Shares of Edwards Lifesciences Corporation (NYSE:EW)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/11/ifp-advisors-inc-purchases-447-shares-of-edwards-lifesciences-corporation-nyseew.html.

A number of equities research analysts have recently commented on EW shares. Jefferies Group LLC reissued a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Wednesday, April 26th. Vetr cut Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $124.67 target price on the stock. in a research note on Monday, May 15th. Royal Bank Of Canada reissued a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Tuesday, May 30th. Bank of America Corporation increased their target price on Edwards Lifesciences Corporation from $120.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, May 30th. Finally, Zacks Investment Research raised Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 target price on the stock in a research note on Monday, May 22nd. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. Edwards Lifesciences Corporation has an average rating of “Buy” and an average target price of $121.13.

In other Edwards Lifesciences Corporation news, VP Patrick B. Verguet sold 22,631 shares of the business’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $113.16, for a total transaction of $2,560,923.96. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $118.05, for a total value of $3,883,845.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 183,412 shares of company stock worth $21,176,230. Company insiders own 2.13% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.